Previous 10 | Next 10 |
Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for peripheral and coronary vascular disease, today announced that it has appointed Jeffery W. Chambers, M.D., as Chief Medical Officer....
Cardiovascular Systems (NASDAQ:CSII) has collaborated with Innova Vascular to develop a full line of novel thrombectomy devices. Thrombectomy is an interventional procedure performed to remove blood clots from arteries and veins. The company intends to acquire and commercialize novel thr...
Mechanical and aspiration devices to treat peripheral vascular disease, deep vein thrombosis and pulmonary embolism Cardiovascular Systems, Inc. (CSI ® ) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatm...
Image source: The Motley Fool. Cardiovascular Systems (NASDAQ: CSII) Q2 2022 Earnings Call Feb 03, 2022 , 9:00 a.m. ET Operator Continue reading For further details see: Cardiovascular Systems (CSII) Q2 2022 Earnings Call Transcript
Cardiovascular Systems, Inc. (CSII) Q2 2022 Earnings Conference Call February 03, 2022, 09:00 AM ET Company Participants Jack Nielsen - VP, IR Scott Ward - Chairman, President, CEO Jeff Points - CFO Rhonda Robb - COO Conference Call Participants Mathew Blackman - Stifel Chris Pasquale - Gugge...
The following slide deck was published by Cardiovascular Systems, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Cardiovascular Systems, Inc. 2022 Q2 - Results - Earnings Call Presentation
Cardiovascular Systems press release (NASDAQ:CSII): Q2 GAAP EPS of -$0.23 misses by $0.09. Revenue of $59.1M (-7.9% Y/Y) misses by $3.56M. For the fiscal year ending June 30, 2022, CSI anticipates: Revenue of $235 million to $245 million from prior guidance of $265 million to $285 millio...
Conference Call Scheduled for Today, February 3, 2022, at 8:00 a.m. CT (9:00 a.m. ET) Revenues of $59.1 million increased 1.3% sequentially compared to first quarter this year and decreased 7.8% compared to second quarter last year Procedure volumes adversely impacte...
Cardiovascular Systems, Inc. (CSI ® ) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management plans to present and host inve...
Complementary technology to orbital atherectomy expands CSI’s vessel prep market opportunity Cardiovascular Systems, Inc. (CSI ® ) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for ...
News, Short Squeeze, Breakout and More Instantly...
Cardiovascular Systems Inc. Company Name:
CSII Stock Symbol:
NASDAQ Market:
Cardiovascular Systems Inc. Website:
Cytek Biosciences Set to Join S&P SmallCap 600 Cytek Biosciences Set to Join S&P SmallCap 600 PR Newswire NEW YORK , April 25, 2023 /PRNewswire/ -- Cytek Biosciences Inc (NASD:CTKB) will replace Cardiovascular Systems Inc. (NASD:CSII) in the S&P S...
Largest randomized coronary atherectomy trial ever conducted Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today...
NEW YORK, NY / ACCESSWIRE / April 2, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: INDUS Realty Trust, Inc. (NASDAQ:I...